Cargando…
Metformin: A New Inhibitor of the Wnt Signaling Pathway in Cancer
The biguanide drug metformin is widely used in type 2 diabetes mellitus therapy, due to its ability to decrease serum glucose levels, mainly by reducing hepatic gluconeogenesis and glycogenolysis. A considerable number of studies have shown that metformin, besides its antidiabetic action, can improv...
Autores principales: | Conza, Domenico, Mirra, Paola, Fiory, Francesca, Insabato, Luigi, Nicolò, Antonella, Beguinot, Francesco, Ulianich, Luca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486775/ https://www.ncbi.nlm.nih.gov/pubmed/37681914 http://dx.doi.org/10.3390/cells12172182 |
Ejemplares similares
-
Metformin Dysregulates the Unfolded Protein Response and the WNT/β-Catenin Pathway in Endometrial Cancer Cells through an AMPK-Independent Mechanism
por: Conza, Domenico, et al.
Publicado: (2021) -
Diabetes and Cognitive Impairment: A Role for Glucotoxicity and Dopaminergic Dysfunction
por: Pignalosa, Francesca Chiara, et al.
Publicado: (2021) -
Dicarbonyl Stress at the Crossroads of Healthy and Unhealthy Aging
por: Nigro, Cecilia, et al.
Publicado: (2019) -
PED/PEA-15 Inhibits Hydrogen Peroxide-Induced Apoptosis in Ins-1E Pancreatic Beta-Cells via PLD-1
por: Fiory, Francesca, et al.
Publicado: (2014) -
The Pervasive Effects of ER Stress on a Typical Endocrine Cell: Dedifferentiation, Mesenchymal Shift and Antioxidant Response in the Thyrocyte
por: Ulianich, Luca, et al.
Publicado: (2020)